Aileron Therapeutics shares are trading higher after Ladenburg Thalmann maintained a Buy rating on the stock and raised its price target from $9 to $19. Also, the company filed U.S. Patent Application number 20240124518 titled "Methods For Preparing Purified Polypeptide Compositions"
Portfolio Pulse from Benzinga Newsdesk
Aileron Therapeutics' stock price increased following an upgrade by Ladenburg Thalmann, which maintained a Buy rating and raised the price target from $9 to $19. Additionally, the company filed a U.S. Patent Application for 'Methods For Preparing Purified Polypeptide Compositions'.
April 18, 2024 | 4:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aileron Therapeutics sees a positive stock movement after an analyst upgrade and a significant price target increase, coupled with a new patent application filing.
The upgrade by Ladenburg Thalmann, including a substantial increase in the price target, signals strong confidence in Aileron Therapeutics' future prospects, likely leading to increased investor interest and a positive short-term price movement. The filing of a new patent application may also contribute to positive sentiment by highlighting the company's ongoing innovation and potential for future revenue streams.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100